2-氯-N,N-二甲基-4-吡啶羧酰胺 | 209262-63-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-N,N-二甲基-4-吡啶羧酰胺
• 中文别名: 2-氯-N,N-二甲基吡啶-4-甲酰胺
• 英文名称: 2-chloro-N,N-dimethylisonicotinamide
• 英文别名: N,N-dimethyl-2-chloro-pyridine-4-carboxamide；2-chloro-N,N-dimethylisonicotineamide；2-chloro-N,N-dimethylpyridine-4-carboxamide
• CAS: 209262-63-5
• 化学式: C₈H₉ClN₂O
• mdl: MFCD03411707
• 分子量: 184.625
• InChiKey: WSLAJZPKKCKUDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  33.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-氯-N,N-二甲基-4-吡啶羧酰胺 在 盐酸 、 正丁基锂 、 sodium hydride 、 一水合肼 、 红铝 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-hydrazino-4-(3-hydroxymethyl-6,7-dimethoxyisoquinolin-1-yl)pyridine
  参考文献：
  名称：

  Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors

  摘要：

  A novel series of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives has been prepared. These compounds showed potent PDE4 inhibitory activities and a broad margin between the K-i value of the rolipram binding affinity and the IC50 value of PDE4 inhibition. They also exhibited potent inhibitory activities toward LPS-induced TNF-alpha production in mice. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00438-4
• 作为产物：
  描述：

  2-氯吡啶-N-氧化物 在 dipotassium peroxodisulfate 、 3-(diphenylphosphoryl)-6-methoxy-1-methylquinolin-2(1H)-one 、 碳酸氢钠 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 6-chloro-N,N-dimethylpicolinamide 、 2-氯-N,N-二甲基-4-吡啶羧酰胺
  参考文献：
  名称：

  喹啉酮通过可见光驱动光催化对吡啶衍生物进行位点选择性功能化

  摘要：

  在吡啶支架上选择性安装膦酰基和氨基甲酰基部分是合成和药物化学中的一个重要转变。通过使用喹啉酮作为一种高效的有机光催化剂，我们开发了一种由可见光驱动的催化体系，该体系形成膦酰基和氨基甲酰基自由基，在温和、无过渡金属的条件下与各种杂芳烃衍生物反应。这种直接且环保的合成方法代表了一种位点发散的吡啶功能化的新方法，在简单性和效率方面具有相当大的优势。环境温度足以形成反应性自由基，并且可以通过改变自由基偶联源将位点选择性从 C2 切换到 C4。在标准反应条件下，膦酰基自由基可提供 C4 产物，而氨基甲酰基自由基可选择性地产生 C2 产物。我们发现氨基甲酰基自由基通过允许氨基甲酰基自由基的氧代官能团以静电方式与吡啶鎓底物的氮结合，从而优先产生邻位产物，从而克服了形成邻位产物的内在偏好。膦酰基不能参与相同的相互作用，因为磷太大。这种新颖的合成路线可耐受广泛的底物，并为访问众多特权支架的核心结构提供了方便

  DOI：

  10.1021/jacs.9b02013

文献信息

• 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE
  申请人：Horiuchi Yoshihiro

  公开号：US20120225876A1

  公开（公告）日：2012-09-06

  Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R 1a and R 1b may be the same or different and each independently represents a C 1-6 alkyl group which may be substituted by one to three halogen atoms; m and n each independently represents an integer of 0-5; X 1 represents a hydroxyl group or an aminocarbonyl group; Z 1 represents a single bond or the like; and R 2 represents an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group or the like.)

  公开了一种由公式(1)表示的化合物或其药理可接受的盐(在公式中，A代表由公式(A-1)表示的基团；R1a和R1b可以相同或不同，每个独立地表示一个可以由一个到三个卤素原子取代的C1-6烷基；m和n各自独立地表示0-5之间的整数；X1代表羟基或氨基甲酰基；Z1代表单键等；R2代表一个可选地取代的C1-6烷基，一个可选地取代的C6-10芳基等)。
• [EN] PYRIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR TREATING DISEASES RELATED TO MCH RECEPTOR<br/>[FR] DERIVES DE PYRIDINE ET LEUR UTILISATION EN TANT QUE MEDICAMENTS POUR LE TRAITEMENT DES MALADIES LIEES AUX RECEPTEURS MCH
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2006035967A1

  公开（公告）日：2006-04-06

  The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涵盖了化学式（I）的新型取代吡啶化合物，其作为MCH受体拮抗剂。这些组合物及其药物组合物在预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴饮暴食障碍包括暴食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾症方面具有用处。
• BROADSPECTRUM 2-(SUBSTITUTED-AMINO)-BENZOXAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS
  申请人：SURLERAUX Nestor Ghislain Dominique Louis

  公开号：US20070135447A1

  公开（公告）日：2007-06-14

  The present invention concerns the compounds having the formula N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R 1 and R 8 each are H, optionally substituted C 1-6 alkyl, C 2-6 alkenyl, C 3-7 cycloalkyl, aryl, Het 1 , Het 2 ; R 1 may also be a radical of formula (R 11a R 11b )NC(R 10a R 10b )CR 9 —; t is 0, 1 or 2; R 2 is H or C 1-6 alkyl; L is —C(═O)—, —O—C(═O)—, —NR 8 —C(═O)—, —O—C 1-6 alkanediyl-C(═O)—, —NR 8 —C 1-6 alkanediyl-C(═O)—, —S(═O) 2 —, —O—S(═O) 2 —, —NR 8 —S(═O) 2 ; R 3 is C 1-6 alkyl, aryl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, or arylC 1-4 alkyl; R 4 is H, C 1-4 alkylOC(═O), carboxyl, aminoC(═O), mono- or di(C 1-4 alkyl)aminoC(═O), C 3-7 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl or optionally substituted C 1-6 alkyl; A is C 1-6 alkanediyl, —C(═O)—, —C(═S)—, —S(═O) 2 —, C 1-6 alkanediyl-C(═O)—, C 1-6 alkanediyl-C(═S)— or C 1-6 alkanediyl-S(═O) 2 —; R 5 is H, OH, C 1-6 alkyl, Het 1 C 1-6 alkyl, Het 2 C 1-6 alkyl, optionally substituted aminoC 1-6 alkyl; R 6 is C 1-6 alkylO, Het 1 , Het 1 O, Het 2 , Het 2 O, aryl, arylO, C 1-6 alkyloxycarbonylamino or amino; and in case -A- is other than C 1-6 alkanediyl then R 6 may also be C 1-6 alkyl, Het 1 C 1-4 alkyl, Het 1 OC 1-4 alkyl, Het 2 C 1-4 alkyl, Het 2 OC 1-4 alkyl, arylC 1-4 alkyl, arylOC 1-4 alkyl or aminoC 1-4 alkyl; whereby each of the amino groups in the definition of R 6 may optionally be substituted; -A-R 6 is hydroxyC 1-6 alkyl; R 5 and -A-R 6 taken together with the nitrogen atom to which they are attached may also form Het 1 or Het 2 It further relates to their use as broadspectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with another anti-retroviral agent, and to their use in assays as reference compounds or as reagents.

  本发明涉及具有以下式N-氧化物，盐，立体异构体，外消旋混合物，前药，酯和其代谢物，其中R1和R8各自为H，可选择性取代的C1-6烷基，C2-6烯基，C3-7环烷基，芳基，Het1，Het2; R1也可以是式（R11aR11b）NC（R10aR10b）CR9—的基团; t为0，1或2; R2为H或C1-6烷基; L为—C（═O）—，—O—C（═O）—，—NR8—C（═O）—，—O—C1-6烷二基-C（═O）—，—NR8—C1-6烷二基-C（═O）—，—S（═O）2—，—O—S（═O）2—，—NR8—S（═O）2; R3为C1-6烷基，芳基，C3-7环烷基，C3-7环烷基C1-4烷基，或芳基C1-4烷基; R4为H，C1-4烷基OC（═O），羧基，氨基C（═O），单烷基或双烷基氨基C（═O），C3-7环烷基，C2-6烯基，C2-6炔基或可选择性取代的C1-6烷基; A为C1-6烷二基，—C（═O）—，—C（═S）—，—S（═O）2—，C1-6烷二基-C（═O）—，C1-6烷二基-C（═S）—或C1-6烷二基-S（═O）2—; R5为H，OH，C1-6烷基，Het1C1-6烷基，Het2C1-6烷基，可选择性取代的氨基C1-6烷基; R6为C1-6烷基氧，Het1，Het1氧，Het2，Het2氧，芳基，芳基氧，C1-6烷氧羰基氨基或氨基; 如果-A-不是C1-6烷二基，则R6也可以是C1-6烷基，Het1C1-4烷基，Het1OC1-4烷基，Het2C1-4烷基，Het2OC1-4烷基，芳基C1-4烷基，芳基OC1-4烷基或氨基C1-4烷基; 其中定义R6中的每个氨基可选择性取代; -A-R6为羟基C1-6烷基; R5和-A-R6与它们所连接的氮原子一起还可以形成Het1或Het2。它进一步涉及它们作为广谱HIV蛋白酶抑制剂的用途，它们的制备过程以及包含它们的制药组合物和诊断试剂盒。它还涉及与另一种抗逆转录病毒药物的组合以及它们作为参考化合物或试剂在测定中的用途。
• Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
  申请人：Sekiguchi Yoshinori

  公开号：US20080090863A1

  公开（公告）日：2008-04-17

  The present invention encompasses novel substituted pyridine compounds of Formula (I): which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涵盖了式（I）的新型取代吡啶化合物，其作为MCH受体拮抗剂。这些组合物及其制药组合物在预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和饮食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食障碍，包括贪食症、厌食症、精神障碍，包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍，包括帕金森病、癫痫和成瘾方面具有用处。
• Pharmaceutical pyridine derivatives, processes for preparing the same and intermediates therefor
  申请人：TANABE SEIYAKU CO., LTD.

  公开号：EP0848000A1

  公开（公告）日：1998-06-17

  A pyridine derivative of the formula (I): wherein A is group of the following formulae: R1 and R2 are each H, or protected or unprotected OH, R31, R41 and R42 are protected or unprotected hydroxymethyl, R32 is H, lower alkyl, or protected or unprotected hydroxymethyl, R33 is substituted or unsubstituted lower alkyl, and the dotted line means the presence or absence of a double bond' R5 and R6 are H, or protected or unprotected amino, or both combine together with the adjacent nitrogen to form substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof, show excellent bronchoconstriction inhibitory activity and/or anti-inflammatory activity of airways, and are , useful in the prophylaxis or treatment of asthma.

  式（I）的吡啶衍生物： 其中 A 为下式中的基团： R1 和 R2 分别为 H，或受保护或未受保护的 OH，R31、R41 和 R42 为受保护或未受保护的羟甲基，R32 为 H、低级烷基或受保护或未受保护的羟甲基，R33 为取代或未取代的低级烷基，虚线表示存在或不存在双键' R5 和 R6 为 H、或受保护或未受保护的氨基，或两者与相邻的氮结合在一起形成取代或未取代的杂环，或其药学上可接受的盐，显示出优异的支气管收缩抑制活性和/或气道抗炎活性，可用于预防或治疗哮喘。